Form 4: Entrada Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
An executive at Entrada Therapeutics, Natarajan Sethuraman, sold a total of 15,891 shares of common stock over three days under a pre-arranged 10b5-1 trading plan.
Summary
- Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics, sold 100 shares of common stock on November 29, 2024, at $20 per share.
- He then sold 4,088 shares on December 2, 2024, at a weighted average price of $20.2626 per share, with individual sales ranging from $20.00 to $20.43.
- Finally, on December 3, 2024, he sold 11,703 shares at a weighted average price of $20.1475 per share, with individual sales ranging from $20.02 to $20.34.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these sales, Sethuraman directly owns 144,997 shares of Entrada Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock sales by an executive under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.
Risks
- Executive stock sales can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies, often executed under pre-arranged trading plans to avoid accusations of insider trading. This filing is a routine disclosure of such activity.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies to manage their personal finances while avoiding potential insider trading issues.
- The reported sales are within the typical range of executive stock transactions and do not appear to be unusual compared to similar filings from other biotech companies.
Stakeholder Impact
- The stock sales may have a minor impact on the stock price, but the pre-arranged nature of the sales should mitigate any significant negative reaction from shareholders.
Key Dates
| Date | Description |
|---|---|
| 2023-12-14 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2024-11-29 | Date of the first reported stock sale. |
| 2024-12-02 | Date of the second reported stock sale. |
| 2024-12-03 | Date of the third reported stock sale and the filing date of the Form 4. |
Keywords
Entrada Therapeutics, stock sale, Form 4, insider trading, 10b5-1 plan, Natarajan Sethuraman, executive stock, TRDA
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.